Skip to content
Catalyst

knowcompoundscyanocob(III)alamin

Specimen compound organic compound

Cyanocobalamin (vitamin B12)

A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water.

Continue

Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues. Intrinsic factor is important for the assimilation of vitamin B 12.”

fig. 1Cyanocobalamin (vitamin B12) · findings by direction and evidence strength
Formula
C63H88CoN14O14P
Molar mass
1355.388 g/mol
InChIKey
RMRCNWBMXRMIRW-WZHZPDAFSA-L

↑ raised 6 findings in 5 endpoints · ↓ lowered 3 in 2 · – no difference found 5 in 5

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
5
Limited
1
Very limited
8
Insufficient
0

How to read these marks

Fig. 2 Cyanocobalamin (vitamin B12) CHEBI:17439 11 endpoints 14 findings
×1.60
Labels
CompoundInspector

Cyanocobalamin (vitamin B12)

Most findings

  • All-cause mortality×2
  • Plasma total homocysteine (tHcy) concentration×2
  • Serum vitamin B12 (cobalamin) concentration×2
  • Alanine aminotransferase×1
Show the remaining 7Show the first 4
  • Fasting blood glucose×1
  • Health-related quality of life×1
  • Lung cancer incidence×1
  • Malondialdehyde (circulating)×1
  • Numeric rating scale (NRS) pain intensity×1
  • Prostate cancer incidence×1
  • Total sleep time×1

1 reference statement, not drawn · 36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. Plasma total homocysteine (tHcy) concentration
  2. Alanine aminotransferase
  3. Fasting blood glucose
  4. Malondialdehyde (circulating)
  5. Prostate cancer incidence
  6. Lung cancer incidence
  7. All-cause mortalitycontested
  8. Serum vitamin B12 (cobalamin) concentration
  9. Health-related quality of life
  10. Numeric rating scale (NRS) pain intensity
  11. Total sleep time
Show the remaining 3Show the first 8
fig. 3 · 11 endpoints · 14 findingscontested · an endpoint whose findings disagree

02 · contested · 1 endpoint

Where the findings disagree

  1. 012 findings

    All-cause mortality

    – no difference found
    1
    ↑ raised
    1

03 · findings

What cyanocobalamin (vitamin B12) moved, and by how much

  • OR odds ratio · MD mean difference · HR hazard ratio. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  • Industry funding: named on its row.
Direction
Strength, at least

12 of 14 shown

  1. Alanine aminotransferaseMoved: no difference foundEvidence: ModeratePaper: PMID 359821622022Industry funded
    Who
    Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
    Dose studied
    1000 µg cyanocobalamin, one oral tablet daily for 12 weeks

    Although serum levels of ALT in the vitamin B12 group decreased significantly, this change did not reach a significant level compared to the placebo group.”

    Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.RCT · 3 monthsPermalink
  2. Fasting blood glucoseMoved: no difference foundEvidence: ModeratePaper: PMID 359821622022Industry funded
    Who
    Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
    Dose studied
    1000 µg cyanocobalamin, one oral tablet daily for 12 weeks

    In the vitamin B12 group, the levels of FBG significantly decreased; however, the between-group comparison revealed a nonsignificant P-value (P = 0.167).”

    Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.RCT · 3 monthsPermalink
  3. Malondialdehyde (circulating)Moved: no difference foundEvidence: ModeratePaper: PMID 359821622022Industry funded
    Who
    Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
    Dose studied
    1000 µg cyanocobalamin, one oral tablet daily for 12 weeks

    The serum levels of MDA were reduced significantly in the vitamin B12 group; however, this change was not significant compared to the placebo group (Table 4).”

    Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.RCT · 3 monthsPermalink
  4. Prostate cancer incidenceMoved: raisesEvidence: ModeratePaper: PMID 205017712010
    Who
    Men in a nested case-control study (ProtecT, 1,461 cases and 1,507 controls) pooled with published studies; exposure is circulating B12 concentration
    Dose studied
    not reported

    Vitamin B(12) and (in cohort studies) folate were associated with increased prostate cancer risk.”

    Quoted verbatim from Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis.meta-analysisPermalink
  5. Plasma total homocysteine (tHcy) concentrationMoved: lowersEvidence: Moderatereplicated ×1Paper: PMID 202165602010Industry funded
    Who
    Indian children (mean age 9 y) and their parents from 119 rural families of the Pune Maternal Nutrition Study; B12 arms (B2, B10) compared with the no-B12 arm (B0), with folic acid 0 or 200 μg distributed across all B12 arms (factorial design, arms pooled over folic acid); 12 months, tHcy by fluorescence polarization immunoassay on fasting plasma
    Dose studied
    vitamin B12 2 μg or 10 μg capsule orally daily before breakfast, for 12 months

    Plasma tHcy concentrations fell in the B2 and B10 groups, and showed little change in the B0 group.”

    Quoted verbatim from Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India.RCT · 12 monthsPermalink
  6. Lung cancer incidenceMoved: raisesEffect, as reportedOR1.15[1.06 to 1.25]Evidence: LimitedPaper: PMID 304991352019
    Who
    5183 lung cancer cases and matched controls nested within 20 prospective cohorts (Lung Cancer Cohort Consortium); pre-diagnostic circulating vitamin B12, per doubling, overall lung cancer
    Dose studied
    not reported

    Directly measured circulating vitamin B12 was positively associated with overall lung cancer risk in the LC3 consortium (OR for a doubling in vitamin B12 [ORlog2B12] = 1.15, 95% confidence interval [95%CI] = 1.06-1.25, Figure 1).”

    Quoted verbatim from Is high vitamin B12 status a cause of lung cancer?case-controlPermalink
  7. Serum vitamin B12 (cobalamin) concentrationMoved: raisesEffect, as reportedMD68.53[41.83 to 95.23]Evidence: Very limitedreplicated ×1Paper: PMID 422273072026
    Who
    Children under 12 years in randomised trials of oral vitamin B12 alone versus placebo, pooled · n = 705
    Dose studied
    not reported

    Vitamin B12 supplementation in children reduces vitamin B12 deficiency (absolute risk difference (ARD) 56 fewer per 1000, 95% CI 68 fewer to 24 fewer; 1.8% versus 7.6%; risk ratio (RR) 0.27, 95% CI 0.11 to 0.69; 3 trials, 642 children; high-certainty evidence), and probably increases total vitamin B12 concentrations (MD 68.53 pmol/L, 95% CI 41.83 to 95.23; 7 trials, 705 children; moderate-certainty evidence), compared to placebo, with an average increase of 68.5 pmol/L.”

    Quoted verbatim from Vitamin B12 supplementation for growth, development, and cognition in children.meta-analysisPermalink
  8. Serum vitamin B12 (cobalamin) concentrationMoved: raisesEvidence: Very limitedreplicated ×1Paper: PMID 245988852014
    Who
    Pregnant women under 14 weeks of gestation in Bangalore, India, all given iron and folic acid throughout pregnancy in both arms; plasma B12 at the second and third trimesters
    Dose studied
    vitamin B-12 50 μg orally daily from before 14 weeks of gestation through 6 weeks postpartum

    Compared with placebo recipients, vitamin B-12-supplemented women had significantly higher plasma vitamin B-12 concentrations at both the second (median vitamin B-12 concentration: 216 vs. 111 pmol/L, P < 0.001) and third (median: 184 vs. 105 pmol/L, P < 0.001) trimesters.”

    Quoted verbatim from Vitamin B-12 supplementation during pregnancy and early lactation increases maternal, breast milk, and infant measures of vitamin B-12 status.RCTPermalink
  9. All-cause mortalitycontestedMoved: raisesEffect, as reportedHR1.5[1.29 to 1.74]Evidence: Very limitedPaper: PMID 382527872024
    Who
    Pooled cohort studies of adults; high circulating serum vitamin B12 category (>600 pmol/L) versus the reference category; no one was dosed
    Dose studied
    not reported

    The meta-analysis of cohort studies showed a positive association between a high serum vitamin B12 concentration (>600 pmol/L) and all-cause mortality (adjusted HR 1.50, 95 % CI 1.29 to 1.74; n = 10; p < 0.01), CVD mortality (adjusted HR 2.04, 95 % CI 0.99 to 4.19; n = 2; p = 0.02), except cancer mortality (adjusted HR 1.56, 95 % CI 0.82 to 2.95; n = 3).”

    Quoted verbatim from The origin of vitamin B12 levels and risk of all-cause, cardiovascular and cancer specific mortality: A systematic review and dose-response meta-analysis.meta-analysisPermalink
  10. Health-related quality of lifeMoved: raisesEvidence: Very limitedPaper: PMID 304778532018
    Who
    Patients with postherpetic neuralgia; pooled randomised trials of vitamin B12 against placebo
    Dose studied
    not reported

    Vitamin B12 administration improved the quality of life of PHN patients with moderate quality evidence and significantly decreased the number of patients using analgesics.”

    Quoted verbatim from Vitamin B12 for herpetic neuralgia: A meta-analysis of randomised controlled trials.meta-analysisPermalink
  11. Numeric rating scale (NRS) pain intensityMoved: lowersEffect, as reportedMD−4.01[−4.7 to −3.33]Evidence: Very limitedPaper: PMID 304778532018
    Who
    Patients with postherpetic neuralgia; pooled randomised trials of vitamin B12 against placebo
    Dose studied
    not reported

    Compared with the placebo group, the Vitamin B12 group exhibited a significant decrease in the Numeric Rating Scale score, with a mean difference of -4.01 (95% confidence interval = -4.70 to -3.33).”

    Quoted verbatim from Vitamin B12 for herpetic neuralgia: A meta-analysis of randomised controlled trials.meta-analysisPermalink
  12. All-cause mortalitycontestedMoved: no difference foundEffect, as reportedHR0.74[0.49 to 1.11]Evidence: Very limitedPaper: PMID 332980542020Industry funded
    Who
    1533 community-dwelling Dutch adults aged 60-75 years in the Lifelines-MINUTHE subcohort; baseline serum vitamin B12 (per doubling) against all-cause mortality over a median 5.3 years; univariable Cox analysis · n = 1,533
    Dose studied
    not reported

    In univariable Cox regression analyses, we found a significant association of log2 MMA with mortality (HR 1.67 (95% CI 1.25–2.22), P < 0.001) and eGFR (per 10 mL/min/1.73 m2) with mortality (0.73 (0.62–0.85), P < 0.001), while log2 vitamin B12 was not significantly associated with mortality (0.74 (0.49–1.11), P = 0.1).”

    Quoted verbatim from Methylmalonic acid, vitamin B12, renal function, and risk of all-cause mortality in the general population: results from the prospective Lifelines-MINUTHE study.cohortPermalink

No dose is advised.

  • OR odds ratio · MD mean difference · HR hazard ratio. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  • Industry funding: named on its row.

04 · identity

Structure

fig. 4Cyanocobalamin (vitamin B12) · 2D structure · ChEBI’s SMILES
Charge
0
3D model
None at PubChem
SMILES
[H][C@]12[C@H](CC(N)=O)[C@@]3(C)CCC(=O)NC[C@@]([H])(C)OP(=O)([O-])O[C@H]4[C@@H](O)[C@H](O[C@@H]4CO)n4c[n+](c5cc(C)c(C)cc54)[Co-3]456([C]#N)[N]1C3=C(C)C1=[N+]4C(=CC3=[N+]5C(=C(C)C4=[N+]6[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O

05 · reach

What it touches on the way

1 entity · assembled from reference reactions

  1. MMACHCProtein13 paths · 13 endpointsinferred

06 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Liver injury · LiverTox
EUnlikely cause of liver injury
NBK547852 · transcribed, not assessed
Reference statements
101 ProteinMMACHCinferred, one hop from cyanocobalamin (vitamin B12)
Reactions · Rhea
1reaction
1Reference statement

What the reference databases state

Evidence key

Regulatory determinations

  • LiverTox likelihood score ELiverTox

    LiverTox Likelihood Score E — despite extensive use, no evidence that the agent has caused liver injury. Chapter: "Vitamin B". Source: LiverTox Master List (NBK571102).

    The document·Public Domain (NLM/NIH)·Transcribed, not assessed

Statements

1 statement

cyanocob(III)alamin is a substrate of each · 1 of 2 reference databases · Sources: Rhea

1Reaction

07 · on the label · 7,887 products

Labelled products

Source: NIH DSLD · Ingredient: cyanocob(III)alamin · 7,887 products · Declared amount per serving (the first 1,000 shown): 0.2–1,000,000 µg

970 labels of the first 1,000 shown state an amount30 do not

  • 1st PhormM-Factor HeroVitamin B12, as Cyanocobalamin50 µgper 3 capsulesDSLD:12881
  • 21st CenturyDiabetic Support FormulaVitamin B12, as Cyanocobalamin25 µgper 3 tabletsDSLD:11189
  • 21st CenturyOne Daily ActiveVitamin B12, as Cyanocobalamin18 µgper 1 tabletDSLD:11548
  • 21st CenturyOne Daily Adults 50+Vitamin B12, as Cyanocobalamin25 µgper 1 tabletDSLD:11549
  • 21st CenturyOne Daily Cholesterol Health With PolicosanolVitamin B12, as Cyanocobalamin6 µgper 1 tabletDSLD:11550
  • 21st CenturyOne Daily EnergyVitamin B12, as Cyanocobalamin12 µgper 1 tabletDSLD:11552
  • 21st CenturyOne Daily EssentialVitamin B-12, as Cyanocobalamin6 µgper 1 tabletDSLD:11556
  • 21st CenturyOne Daily MaximumVitamin B12, as Cyanocobalamin6 µgper 1 tabletDSLD:11558
  • 21st CenturyOne Daily Men's HealthVitamin B12, as Cyanocobalamin18 µgper 1 tabletDSLD:11559
  • 21st CenturyOne Daily Weight ControlVitamin B12, as Cyanocobalamin7.5 µgper 1 tabletDSLD:11560
  • 21st CenturyOne Daily Women'sVitamin B12, as Cyanocobalamin6 µgper 1 tabletDSLD:11561
  • 21st CenturyOne Daily Women's 50+Vitamin B12, as Cyanocobalamin25 µgper 1 tabletDSLD:11497
Show the remaining 7,875Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

08 · the record

Sources

726

papers screened for cyanocobalamin (vitamin B12)

admitted
14
read and discarded
410
not read yet
302

The screening record, every paper and why

Sources cited

11 papers · 14 findings

3 admitted at screening, no finding yet

Show every paper citedHide the papers cited

Other names · 8

CN-Cbl · CO-CYANOCOBALAMIN · cyanocobalamin · Dicopac · vitamin B-12 · Vitamin B12 complex

systematic · Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-cyanocobamide

systematic · Coα-[α-(5,6-dimethylbenzimidazolyl)]-Coβ-cyanocobamide